Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

6(85.7%)

Phase 3

1(14.3%)

7Total

Phase 2(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00495287Phase 3Completed

A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

Role: lead

NCT00795756Phase 2Completed

Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

Role: lead

NCT01290120Phase 2Completed

Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma

Role: lead

NCT00400673Phase 2Completed

A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia

Role: lead

NCT00358072Phase 2Completed

Treatment of Adult ALL With an MRD-directed Programme.

Role: lead

NCT00787384Phase 2Completed

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Role: lead

NCT00501098Phase 2Completed

Prophylaxis of Fungal Invasive Infections in Leukemia

Role: lead

All 7 trials loaded